PHATHOM PHARMACEUTICALS INC. news, videos and press releases
For more news please use our advanced search feature.
PHATHOM PHARMACEUTICALS INC. - More news...
PHATHOM PHARMACEUTICALS INC. - More news...
- Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024
- Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
- Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
- Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
- Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
- Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital
- Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
- Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
- Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
- Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
- Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
- Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
- Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
- Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
- Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application
- Phathom Pharmaceuticals Reports Second Quarter 2023 Results
- Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD
- Phathom Pharmaceuticals Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
- Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
- Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock
- Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock
- Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA
- Phathom Pharmaceuticals Reports First Quarter 2023 Results
- Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023
- Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
- Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch
- Phathom Pharmaceuticals Provides Regulatory Updates
- Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)